Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.81 |
| ▸ | PPARA | Q07869 | 17/20 | 0.81 |
| ▸ | PPARD | Q03181 | 13/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741117 | 0.96 | PPARA (0.74) | PPARGPPARAPPARD | |
| SCHEMBL6736300 | 0.93 | PPARA (0.71) | PPARGPPARAPPARD | |
| SCHEMBL6736299 | 0.93 | PPARA (0.71) | PPARGPPARAPPARD | |
| SCHEMBL6736742 | 0.93 | PPARA (0.71) | PPARGPPARAPPARD | |
| SCHEMBL6736743 | 0.93 | PPARA (0.71) | PPARGPPARAPPARD | |
| SCHEMBL6731610 | 0.92 | PPARA (0.70) | PPARGPPARAPPARD | |
| SCHEMBL6738555 | 0.92 | PPARA (0.77) | PPARGPPARAPPARD | |
| SCHEMBL6735866 | 0.92 | PPARA (0.70) | PPARGPPARAPPARD | |
| SCHEMBL6736526 | 0.92 | PPARA (0.70) | PPARGPPARAPPARD | |
| SCHEMBL6736530 | 0.92 | PPARA (0.70) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683111-B2 | SUCH AS 2-ETHOXY-3-(4-(2-XANTHEN-9-YLIDENE-ETHOXY)-PHENYL)-PROPIONIC ACID; FOR TREATING CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; TREATMENT OF DIABETES/OBESITY | NOVO NORDISK A/S (DK) | 2004-01-27 | — | — | US | claimed |
| US-20020115654-A1 | New compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | claimed |
| EP-1123267-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-08-16 | — | — | EP | claimed |
| WO-2000023415-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | claimed |
| US-8110598-B2 | (+-) Ethyl 3-{4-[2-(pyrrol-1-yl)ethoxy]phenyl}-2-ethoxypropanoate; hyperlipidaemia, hypercholesteremia, hyperglycemia, obesity, impaired glucose intolerance, leptin resistance, insulin resistance, reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma | CADILA HEALTHCARE LIMITED (IN) | 2012-02-07 | — | — | US | disclosed |
| US-8110598-B2 | (+-) Ethyl 3-{4-[2-(pyrrol-1-yl)ethoxy]phenyl}-2-ethoxypropanoate; hyperlipidaemia, hypercholesteremia, hyperglycemia, obesity, impaired glucose intolerance, leptin resistance, insulin resistance, reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma | CADILA HEALTHCARE LIMITED (IN) | 2012-02-07 | — | — | US | disclosed |
| US-7323491-B2 | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2008-01-29 | — | — | US | disclosed |
| US-7323491-B2 | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2008-01-29 | — | — | US | disclosed |
| US-6683111-B2 | SUCH AS 2-ETHOXY-3-(4-(2-XANTHEN-9-YLIDENE-ETHOXY)-PHENYL)-PROPIONIC ACID; FOR TREATING CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; TREATMENT OF DIABETES/OBESITY | NOVO NORDISK A/S (DK) | 2004-01-27 | — | — | US | disclosed |
| US-20020115654-A1 | New compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | disclosed |
| US-6353018-B1 | Compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2002-03-05 | — | — | US | disclosed |
| EP-1123267-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000023415-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115654-A1 | New compounds, their preparation and use | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.